US OptionsDetailed Quotes
CYBN241220P12500
- 3.38
- 0.000.00%
15min DelayClose Nov 27 16:00 ET
0.00High0.00Low
3.38Open3.38Pre Close0 Volume17 Open Interest12.50Strike Price0.00Turnover139.09%IV11.02%PremiumDec 20, 2024Expiry Date2.25Intrinsic Value100Multiplier22DDays to Expiry1.13Extrinsic Value100Contract SizeAmericanOptions Type-0.6561Delta0.1052Gamma3.53Leverage Ratio-0.0284Theta-0.0050Rho-2.32Eff Leverage0.0093Vega
Cybin Stock Discussion
Sign in to post a comment
$Cybin (CYBN.US)$ buying more now 🖕
1
$Cybin (CYBN.US)$👀 more news out on trials 100% effectiveness so far on the therapy drug for treating depression
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86
trading under 12 now seems like something is in the works.
$Vertex Pharmaceuticals (VRTX.US)$ $Astera Labs (ALAB.US)$ $Emergent BioSolutions (EBS.US)$
CCORF Maintains Cybin(CYBN.US) With Buy Rating, Maintains Target Price $86
trading under 12 now seems like something is in the works.
$Vertex Pharmaceuticals (VRTX.US)$ $Astera Labs (ALAB.US)$ $Emergent BioSolutions (EBS.US)$
$Cybin (CYBN.US)$ break the downward wedge LFG 🐂💥🚀
2
$Cybin (CYBN.US)$
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin Inc. (NYSE American:CYBN)reported groundbreaking 12-month efficacy data from its Phase 2 study of CYB003 for major depressive disorder (MDD). After two 16mg doses administered three weeks apart, 100% of participants were responsive to treatment, with 71% in remission at 12 months. The study showed a ~23-point reduction in MADRS depression s...
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin Inc. (NYSE American:CYBN)reported groundbreaking 12-month efficacy data from its Phase 2 study of CYB003 for major depressive disorder (MDD). After two 16mg doses administered three weeks apart, 100% of participants were responsive to treatment, with 71% in remission at 12 months. The study showed a ~23-point reduction in MADRS depression s...
1
$Cybin (CYBN.US)$Cybin Says Phase 2 Data Show Potential Depression Drug Offers Relief Through 1 Year
2
$Cybin (CYBN.US)$ Redacted anyone?
2
No comment yet
DazzlerAus Shatavia Eskdrige077 : I've been following this guy for a while just be clear he is not at all positive in DTJ for longer haul he fix a post election collapse is on the cards
Mr Trecherous OP DazzlerAus :